Instructure Holdings Poised To Dominate Learning Management System Market: KeyBanc

KeyBanc Capital Markets analyst Devin Au initiated coverage on Instructure Holdings, Inc. (NYSE: INST), with an Overweight rating and a 

KeyBanc Capital Markets analyst Devin Au initiated coverage on Instructure Holdings, Inc. (NYSE:INST), with an Overweight rating and a price target of $32.

Au sees “interesting” growth opportunities in international and cross-sells, positioning the company as the vertical leader in the education learning management system, LMS, market.

With ~40% market share in higher ed and ~30% share in K12, Instructure is the LMS market leader in the U.S., the analyst adds.

Given that 40% of U.S. K12 are still using free Learning management system tools, and 70% of international higher educators are utilizing legacy on-prem solutions, there remain vast greenfield opportunities for Instructure to gain shares in the near and long term, notes the analyst.

The analyst notes that Instructure has expanded its product offering to >10 (from solely LMS historically) and has strengthened its cross-sell motion.

The company is also expected to gain from the government funding passed during the pandemic to support education initiatives, which is expected to expire in September 2024, providing INST with near-term adoption catalysts. 

The analyst expects Instructure to expand the EBITDA margin towards 40%, with leverage primarily from improving cost structure and optimizing the on-/off-shore employee mix.

Given the above, the analyst expects FY23 revenues of $524.6 million, while FY24 revenues are expected to be $577.3 million.

Price Action: INST shares are trading higher by 2.4% to $25.63 on the last check Thursday.

Total
0
Shares
Related Posts
Read More

Grand Theft Auto Maker Take-Two Reports Soft Q3 Results, Lowers 2024 Forecast

Take-Two Interactive Software reported quarterly total net bookings of $1.34 billion which is down 3% year-over-year. Take-Two said net bookings from recurrent consumer spending decreased by 7% and accounted for 75% of total net bookings. The company reported GAAP net revenue of $1.37 billion, also down by 3%, and a GAAP loss per share of 54 cents. Take-Two also revised its 2024 net bookings forecast to between $5.25 billion and $5.3 billion.

NXT

Read More

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.

BBIB